Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Abstract Background To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic migraine (CM: ≥ 15 days/month), and multiple preventive treatment failures. Methods This is a prospec...

Full description

Bibliographic Details
Main Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d’Onofrio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Carlo Tomino, Stefania Proietti, Stefano Bonassi, for the FRIEND-Study Group
Format: Article
Language:English
Published: BMC 2023-03-01
Series:The Journal of Headache and Pain
Subjects:
Fremanezumab
Migraine treatment
CGRP monoclonal antibody
Real-world
Long-term treatment
Online Access:https://doi.org/10.1186/s10194-023-01561-w

Internet

https://doi.org/10.1186/s10194-023-01561-w

Similar Items